0000950123-24-012206 Sample Contracts
AURION BIOTECH, INC. LOAN AND SECURITY AGREEMENTLoan and Security Agreement • December 10th, 2024 • Aurion Biotech, Inc. • Biological products, (no disgnostic substances) • New York
This LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into as of February 9, 2024, by and between BANC OF CALIFORNIA, a California state-chartered bank (“Bank”), and AURION BIOTECH, INC., a Delaware corporation (“Borrower”).
150 CAMBRIDGEPARK DRIVE CAMBRIDGE, MASSACHUSETTS LEASE Between PPF OFF 150 CAMBRIDGE PARK DRIVE, LLC, a Delaware limited liability company (“LANDLORD”) AND CORNEAGEN INC., a Delaware corporation (“TENANT”) dated as of September 1, 2021Lease Agreement • December 10th, 2024 • Aurion Biotech, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Lease Agreement (this “Lease”) is made and entered into as of the 1st day of September, 2021 (the “Effective Date”), by and between PPF OFF 150 CAMBRIDGE PARK DRIVE, LLC, a Delaware limited liability company (“Landlord”) and CORNEAGEN INC., a Delaware corporation (“Tenant”).
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...License Agreement • December 10th, 2024 • Aurion Biotech, Inc. • Biological products, (no disgnostic substances) • Washington
This Amended and Restated License Agreement (the “Agreement”), effective as of April 26, 2024 (the “Restatement Date”), is made by and between Dr. Shigeru Kinoshita (“Licensor”), and Aurion Biotech, Inc. (“Aurion”), a Delaware corporation, with offices at 117 E Louisa Street, Suite 561, Seattle, WA, United States, 98102. Each of Licensor and Aurion may be referred to herein as a “Party” or together as the “Parties.”
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Subscription Agreement • December 10th, 2024 • Aurion Biotech, Inc. • Biological products, (no disgnostic substances)
This Subscription Agreement is executed as of June 12, 2020, by Dr. Shigeru Kinoshita (“Subscriber”) in connection with the entry between Subscriber and CorneaGen, Inc., a Delaware corporation (the “Company”) of the Patent License Agreement dated June 12, 2020 (the “Patent License Agreement”).
OFFICE LEASE (One Convention Place)Office Lease • December 10th, 2024 • Aurion Biotech, Inc. • Biological products, (no disgnostic substances) • Washington
THIS OFFICE LEASE (this “Lease”) is made as of the date of last execution by a party (the “Effective Date”), by and between Landlord and Tenant, upon the following terms and conditions:
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Master Development and Manufacturing Services Agreement • December 10th, 2024 • Aurion Biotech, Inc. • Biological products, (no disgnostic substances)
THIS MASTER DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT is made as of April 1, 2021 (the “Effective Date”) by and among CORNEAGEN INC. (“CorneaGen US”), a Delaware corporation, having an address at [Omitted] and its wholly owned subsidiary, CorneaGen Japan, LLC. (“CorneaGen Japan”) (CorneaGen US and CorneaGen Japan referred to collectively as “CorneaGen”) and S-RACMO CO., LTD. (“SR”), a joint venture between Sumitomo Chemical Co., Ltd. and Sumitomo Dainippon Pharma Co., Ltd. (“SUMITOMO”), with offices at 33-94 Enoki-Cho, Suita, Osaka, Japan. CorneaGen and SR are each individually a “Party” and collectively the “Parties.”